Motif Bio to reveal Iclaprim data at Portuguese conference on drug development
MOTIF BIO
£0.01
08:30 29/07/20
Motif Bio will present data on its investigational antibiotic Iclaprim at an upcoming conference on drug development in Lisbon, Portugal.
Motif Bio's chief executive David Huang will unveil new findings on Iclaprim at the conference, held by the European Society of Clinical Microbiology and Infectious Diseases and the American Society For Microbiology.
The conference focuses on the development of new antimicrobial agents for antimicrobial resistance and will be attended by scientists, clinical academics, regulatory bodies, funding bodies and the pharmaceutical industry.
The dual-listed, clinical stage biopharmaceutical company will present its data on 5 September as part of the State of the Art Lecture: New Antibacterial Agents.
Motif Bio's Iclaprim is a novel investigational antibiotic with a targeted gram-positive spectrum of activity. As opposed to the commonly used broad-spectrum antibiotics, Motif claims it's "precision medicine approach" is consistent with antibiotic stewardship principles which seek to reduce the inappropriate use of broad-spectrum.
As of 0825 BST, Motif Bio shares had picked up 2.39% to 34.30p.